Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Start-ups
Sarepta acquires five muscular dystrophy gene therapies from Myonexus
by Ryan Cross
May 13, 2018
| A version of this story appeared in
Volume 96, Issue 20
Sarepta Therapeutics will pay $60 million up front for access to five gene-therapy candidates under development by Myonexus Therapeutics to treat specific forms of muscular dystrophy. Sarepta made a name for itself in treating muscular dystrophy after U.S. FDA approval of its drug eteplirsen in 2016. Myonexus, a spin-off from Nationwide Children’s Hospital in Columbus, Ohio, just raised its first $2.5 million in seed funding in December. The new firm could earn up to $45 million in additional milestone payments in the deal with Sarepta.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter